Transduction Bio Completes Angel+ Round Financing
T-Capital acted as the financial advisor for this round.
In 2021, Transduction Bio announced the completion of its Angel+ round of financing.
This round was co-led by CCB Medical Growth Fund and YuanSheng Ventures, with participation from Hongtai Fund and Huagai Capital.
T-Capital acted as the financial advisor for this round.
The financing will be mainly used to accelerate the company’s RNA drug pipeline development and LNP production platform construction.
Financing Information
| Item | Information |
|---|---|
| Company | Transduction Bio |
| Date | 2021 |
| Round | Angel+ |
| Lead Investors | CCB Medical Growth Fund, YuanSheng Ventures |
| Participating Investors | Hongtai Fund, Huagai Capital |
| Financial Advisor | T-Capital |
| Core Business | RNA Drugs, LNP Delivery Technology |
Transduction Bio: Focusing on RNA Drugs and LNP Delivery Technology
Founded in 2021, Transduction Bio is a biotechnology company focused on RNA drugs and LNP delivery technology.
The company is committed to providing new treatment options for patients through innovative RNA therapies.
RNA Drugs: The Next Generation of Biopharmaceutical Technology
RNA (ribonucleic acid) drugs are a cutting-edge direction in the biopharmaceutical field in recent years.
Unlike traditional drugs, RNA drugs treat diseases by regulating protein expression, and have the advantages of a short development cycle, a wide range of applications, and diverse mechanisms of action.
Currently, RNA drugs have shown great potential in areas such as vaccines, cancer treatment, and genetic diseases.
LNP Delivery Technology: The Key to RNA Drug Development
LNP (Lipid Nanoparticle) is one of the most widely used delivery systems for RNA drugs.
Because RNA molecules are inherently unstable and difficult to enter cells, they need to be delivered to the target through an effective delivery system. LNP technology protects RNA from degradation and helps it to enter cells effectively by encapsulating it in lipid nanoparticles.
A safe and efficient LNP delivery platform is crucial for the successful development of RNA drugs.
Use of Proceeds: Accelerating Pipeline Development and Platform Construction
This round of financing will provide financial support for the development of Transduction Bio, mainly in two aspects:
- Accelerate RNA drug pipeline development: Advance the company’s RNA drug projects under development, especially in the application of vaccines and therapeutics.
- LNP production platform construction: Establish and improve the LNP production process to lay the foundation for subsequent clinical trials and commercial production.
T-Capital as Financial Advisor
In this round of financing for Transduction Bio, T-Capital acted as the financial advisor.
As a capital service institution focusing on the healthcare industry, T-Capital provided professional financing advisory services to Transduction Bio, including:
- Financing strategy advice: Assisting the company in planning its financing path and strategy.
- Investor matching: Precisely matching and connecting with investment institutions interested in the RNA drug field.
- Transaction process support: Assisting the company in completing financing negotiations and transaction execution.
For an early-stage biotechnology company like Transduction Bio, obtaining professional capital market advice during the financing process helps the company to more clearly demonstrate its technological value and development potential to investors.
Investors
The investors in this round include:
- CCB Medical Growth Fund
- YuanSheng Ventures
- Hongtai Fund
- Huagai Capital
These investment institutions have extensive investment experience and industrial resources in the healthcare field, and their participation will provide support for the development of Transduction Bio.
Transaction Highlights
- Completed Angel+ round financing: Providing key financial support for the company’s early development.
- Focus on the cutting-edge field of RNA drugs: The company is committed to the development of RNA drugs and LNP delivery technology.
- Participation of well-known medical investment institutions: Received investment from institutions such as CCB Medical Growth Fund, YuanSheng Ventures, Hongtai Fund, and Huagai Capital.
- T-Capital as financial advisor: Providing professional financing advisory services to the company.
About T-Capital
T-Capital is a service institution focusing on capital transactions and strategic consulting for the healthcare industry.
We provide services such as private financing, mergers and acquisitions, and strategic consulting for healthcare companies, covering multiple fields such as biopharmaceuticals, medical devices, IVD, and medical services.
If you are running a healthcare company and are looking for financing or strategic cooperation, please feel free to contact us.